These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26273639)

  • 1. Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.
    Han F; He J; Li F; Yang J; Wei J; Cho WC; Liu X
    Biomed Res Int; 2015; 2015():672759. PubMed ID: 26273639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advanced Research on MicroRNAs and EGFR-TKIs Secondary Resistance].
    Wang M; Sun Z; Huang L
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):758-63. PubMed ID: 26706953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
    Oxnard GR
    Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer.
    Maftouh M; Avan A; Galvani E; Peters GJ; Giovannetti E
    Crit Rev Oncog; 2013; 18(4):317-26. PubMed ID: 23614618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-targeted therapy.
    Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
    Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
    Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of microRNAs in resistance to lung cancer treatments.
    MacDonagh L; Gray SG; Finn SP; Cuffe S; O'Byrne KJ; Barr MP
    Cancer Treat Rev; 2015 Feb; 41(2):160-9. PubMed ID: 25592062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
    Philip PA; Lutz MP
    Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
    Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of miRNAs that target EGFR mRNA in human lung cancer.
    Yamaguchi G; Takanashi M; Tanaka M; Fujita K; Ohira T; Kuroda M; Ikeda N
    Biochem Biophys Res Commun; 2012 Apr; 420(2):411-6. PubMed ID: 22426479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
    Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung adenocarcinoma: lessons in translation from bench to bedside.
    Sangodkar J; Katz S; Melville H; Narla G
    Mt Sinai J Med; 2010; 77(6):597-605. PubMed ID: 21105123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
    Li SN; Li HQ
    Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.